Page 19 - பல்கலைக்கழகம் ஆஃப் ஆடவா இதயம் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

February 26, 2021 Giving potent antiplatelets up front to ACS patients, regardless of whether they may require CABG, could provide a survival benefit through early induction of platelet quiescence, according to results of a meta-analysis. Senior study author Derek So, MD (University of Ottawa Heart Institute, Ontario, Canada), said the results build on data from the PLATO and TRITON-TIMI 38 trials, both of which suggested potent antiplatelets could bolster survival. Analysis of those two studies plus eight others found greater mortality overall when patients who were admitted for ACS and then underwent CABG had been given weaker antiplatelet strategies, such as aspirin alone or aspirin and clopidogrel, versus potent strategies like aspirin and P2Y12 inhibitors (OR 1.38; 95% CI 1.03-1.85).

United statesFaisal bakaeenKiran sarathyMd university of ottawa heart instituteJournal of the american heart associationUniversity of ottawa heart instituteMd cleveland clinic foundationOttawa heart instituteCleveland clinic foundationAmerican heartProvide someஒன்றுபட்டது மாநிலங்களில்கிறன் சாரதிம்ட் பல்கலைக்கழகம் ஆஃப் ஆடவா இதயம் நிறுவனம்இதழ் ஆஃப் தி அமெரிக்கன் இதயம் சங்கம்பல்கலைக்கழகம் ஆஃப் ஆடவா இதயம் நிறுவனம்